For more than a century, dentistry has focused on repairing or replacing damaged teeth, not growing new ones. That assumption is now under direct challenge, as Japanese teams move a first-of-its-kind drug into human testing that could trigger a natural third set of teeth in people who have lost their own. If the early data hold up, children and adults could be offered a biological alternative to dentures and implants within about four years.
The prospect is not science fiction but the product of targeted molecular research, careful animal studies, and a clear clinical roadmap. Researchers in Japan are betting that by switching specific developmental signals back on, humans may be able to regrow teeth in a way that echoes what happens in sharks or reptiles, but in a controlled, medical setting.
From dental fantasy to clinical trial timeline
The core claim behind the four‑year forecast is simple: if current human trials succeed, a tooth‑regrowth drug could be ready for broader use before the end of this decade. Reporting on the program notes that humans may be able to Humans May Be Able to Grow New Teeth Within Just Years, with the first wave of patients potentially benefiting in roughly four years if safety and efficacy are confirmed. That projected window reflects how long it typically takes to move from early human dosing to a product that regulators can evaluate for routine care.
Specialist dental outlets describe a similar horizon, suggesting that if the current studies stay on track, the medicine could reach patients as a third option alongside prosthetics and implants by around 2030. One analysis notes that, if successful, the treatment could be brought as a new third option to market by 2030, which aligns with the four‑year estimate for initial availability and a slightly longer runway for full commercial rollout.
The Japanese teams betting on a third set of teeth
The push to regrow human teeth is being led by researchers in Japan who have spent years mapping the molecular switches that tell tooth buds when to grow and when to stop. A detailed report on the project explains that By Stan Goff, Senior Content Editor described how Researchers in Japan identified a medicine capable of regrowing a third set of teeth for humans and confirmed that clinical testing has begun. The same coverage stresses that this is not a cosmetic experiment but a targeted therapy for people with missing teeth and congenital dental anomalies.
Other dental commentators have highlighted how Japanese Scientists Begin Human Trials for Tooth Regrowth Drug, with one blog by Ben June framing the work as a shift from imagination to practical medicine. That account invites readers to Imagine a world where, instead of living with gaps or artificial replacements, patients could stimulate their own jaw to produce new teeth. Together, these reports paint a picture of a coordinated Japanese effort that has moved beyond theory into structured human experimentation.
How TRG‑035 tries to flip the body’s “tooth switch”
At the center of the trials is a drug candidate known as TRG‑035, designed to interfere with a protein that normally keeps tooth formation in check. A technical explainer describes TRG as a compound whose innovation lies in how it interacts with a specific protein called USAG, which is involved in regulating tooth development after adult teeth have formed. The same source notes that the program, titled TRG The Tooth Regrowth Drug Explained Its innovation lies in how it targets USAG to restart growth signals that usually go dormant once the second set of teeth is complete.
In animal models, blocking USAG appears to let latent tooth buds continue their development, effectively adding extra teeth in species that normally stop at a certain number. The Japanese group has reported that this mechanism worked in mammals with dental patterns similar to humans, which is why they believe the same approach could translate to people. A separate overview of the program notes that the drug is being positioned as a way to replace missing teeth after adult dentition has developed, rather than as a general enhancer, and that the Unlike reptiles and fish, which usually replace their fangs on a regular basis, humans and other mammals would be using a tightly controlled medical intervention to do something their bodies no longer do on their own.
Why teeth do not naturally grow back like bones
To understand why this drug is so disruptive, it helps to remember how different teeth are from the rest of the skeleton. As one science feature puts it, While bones can regrow themselves when they break, teeth are far less forgiving once enamel and dentin are lost. The same piece, headlined around the idea that Grow New Teeth Within Just Years, stresses that the body treats teeth more like finished tools than living tissue that can be rebuilt on demand, which is why a chipped molar needs a filling instead of a cast.
Dental clinicians add that Realistically, the only way for teeth to regenerate is for the network of dormant genes to be switched back on, something the body can only achieve once during normal development. One practice explains that Jul Realistically, the only way for teeth to regrow is to reactivate those early developmental programs, which is exactly what the Japanese teams are trying to do pharmacologically. That is why the drug targets a regulatory protein like USAG instead of trying to rebuild enamel directly: the goal is to coax the body into repeating a process it normally runs only twice, once for baby teeth and once for adult teeth.
From sharks and reptiles to human smiles
Nature already offers proof that tooth replacement can be a lifelong process, just not in humans. Marine biologists and dentists alike point to sharks, which cycle through rows of teeth throughout their lives, and to reptiles and fish that routinely shed and replace fangs. A clinical explainer on the new drug reminds readers that, Unlike reptiles and fish, which usually replace their fangs on a regular basis, humans and other mammals stop after their second set, which is why any attempt to restart that cycle requires a medical workaround rather than relying on built‑in biology. The Japanese work is essentially an attempt to borrow that regenerative logic without turning people into tooth factories.
Popular explainers have leaned into this comparison with titles like “From Sharks to Smiles,” and one widely shared video segment, From Sharks to Smiles, captures a conversation where a host notes that once a human tooth is gone, the options are pretty much implants or dentures. In that clip, the presenters describe what is really exciting as the possibility that a drug could give people a new, naturally rooted tooth instead of a prosthetic. Another short video titled Regrow Your Teeth Japan’s Breakthrough Discovery underlines that humans and most other mammals only grow two sets of teeth, but did you know that researchers are now testing ways to change that rule, using the Japanese trials as a case study in how quickly regenerative medicine is moving.
Who might benefit first if the drug works
If TRG‑035 proves safe and effective, the first patients are likely to be those with clear medical need rather than people seeking cosmetic upgrades. Dental researchers have emphasized that the initial focus is on congenital conditions where people never develop a full set of teeth, a group that includes children with specific genetic syndromes and adults who have lived for years with gaps. One professional summary notes that the drug is being developed in Dec Share, Japan, where clinicians are targeting tooth anomalies that affect about 0.1% of people, a small but significant population that currently relies heavily on prosthetics.
Over time, the candidate could expand to more common scenarios, such as adults who lose teeth to trauma or decay and want a biological replacement instead of an implant. A detailed overview of the program explains that, if successful, the treatment could become a third option alongside prosthetics and implants, giving dentists a new tool for treating missing teeth. That same analysis, framed around whether patients could grow a third set of teeth by 2030, stresses that While much work remains before regulators approve any such medicine, the potential to offer a living, feeling tooth rather than a static replacement is what makes the trials so closely watched.
What the early human trials are actually testing
For now, the human studies are tightly controlled and focused on safety. Reports on the launch of the program describe how Japanese Scientists Begin Human Trials for Tooth Regrowth Drug with small groups of participants who have specific dental anomalies, rather than healthy volunteers. In one blog, the author notes that the team at the forefront of this study is carefully monitoring how the jaw responds to the drug, how many new tooth buds appear, and whether there are any unintended effects on surrounding tissues, all before considering broader use. That cautious approach reflects the fact that stimulating growth in the mouth is not trivial, since overcrowding or misaligned teeth could create new problems.
Science explainers add that the clinical trials for a drug that replaces missing teeth are finally underway after years of animal work, and that the goal is to see whether the same mechanism that worked in mice and other mammals can be reproduced in people. One summary notes that the researchers are particularly interested in treating tooth anomalies in humans, not in giving everyone a spare set of molars, and that regulators will be watching closely for any signs of off‑target growth. Another widely shared feature, framed around how Humans May Be Able to Grow New Teeth Within Just Years, notes that Japanese researchers are moving forward after seeing promising results in animals with similar dental patterns to humans, which is why they are confident enough to test the drug in people but still cautious about long‑term outcomes.
The promise and limits of a four‑year horizon
Even if everything goes right, the four‑year estimate for real‑world use should be read as an optimistic but conditional forecast. The timeline assumes that the current phase of human trials confirms that TRG‑035 is safe, that follow‑up studies show clear benefits in regrowing functional teeth, and that regulators in Japan and elsewhere are satisfied with the data. Analysts who track dental innovation point out that the projected window in which Humans May Be Able to Grow New Teeth Within Just Years is consistent with other breakthrough therapies that move from early trials to limited clinical use in under a decade, but only when the science is clean and the side‑effect profile is manageable.
There are also practical limits that will shape how quickly patients feel the impact. Manufacturing a biologically active drug at scale, training dentists and oral surgeons to use it appropriately, and deciding which health systems will pay for it are all non‑trivial steps that come after the science. A professional hygiene journal that asks whether patients could grow a third set of teeth by 2030 notes that, While much work remains before any such medicine reaches routine practice, the fact that a concrete path to market by 2030 is even being discussed shows how far the field has moved. In other words, the four‑year horizon is not a guarantee, but it is no longer a fantasy either.
More from MorningOverview